Therapy
Baricitinib
Selective JAK1/JAK2 inhibitor (oral, once daily): blocks multiple cytokine pathways (IL-6, IFN-α/β, GM-CSF) + AAK1 inhibition (reduces viral endocytosis).
Also called: Olumiant, bari, JAK inhibitor
In short
- 1What it is: a therapy in therapies and applications.
- 2How it connects: acts on 4 and is affected by 0 concepts — mostly 1 molecule, 2 disease, 1 trial.
- 3Where it sits: therapy, trial on the 15-step immune chain.
What it does
FDA 2021 boxed warning for JAK inhibitors in patients ≥50y with ≥1 CV risk factor (MACE/VTE/malignancy/infection; ORAL SURVEILLANCE trial).
Its connections at a glance
Each dot is a concept directly linked to Baricitinib. Colours show the kind of concept.
Sources & evidenceloading…
Loading reviewed sources…
Graph ID I014 · concept status: established. Select any connection above to inspect evidence for that specific link.